Symbols

PMN

ProMIS Neurosciences·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Strong Buy"

RSI Oversold

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PMN

Promis Neurosciences Inc.

A company that developing therapeutics for alzheimer's, amyotrophic lateral sclerosis, and parkinson's disease

Industry

Biological Technology

Established Date

01/23/2004

Listing Date

07/08/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.promisneurosciences.com

Security Type

Common stock

Office address

Suite 200 1920 Yonge Street Toronto Ontario M4S 3E2

Business

Introduction

ProMIS Neurosciences Inc., was incorporated on January 23, 2004 under the Canadian Business Corporations Act. The company has been licensed a patented technology platform focusing on the development of antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases. Its platform is designed to selectively target toxic misfolded proteins associated with diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

Company Financials

EPS

PMN has released its 2025 Q4 earnings. EPS was reported at -4.11, versus the expected -4.66, beating expectations. The chart below visualizes how PMN has performed over recent quarters, highlighting trends in earnings surprises.